Thomas Goddard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas Goddard has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Tai
Paediatric Respiratory and Sleep Medicine, Women's and Children's Hospital, University of Adelaide, Adelaide, South Australia, Australia
2 shared publications - Bhavya Papudeshi
Flinders Accelerator for Microbiome Exploration, College of Science and Engineering, Flinders University
2 shared publications - Hubertus Jersmann
Faculty of Health and Medical Sciences, Adelaide Medical School, University of Adelaide
2 shared publications - Jessica A. P. Carlson-Jones
Flinders Accelerator for Microbiome Exploration, College of Science and Engineering, Flinders University
2 shared publications - Judith Morton
Department of Thoracic Medicine, Royal Adelaide Hospital
2 shared publications - Katrine L. Whiteson
Department of Molecular Biology and Biochemistry, University of California, Irvine, California, USA
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 39 (3)
DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation
SUMMARY: DNA sequencing has revolutionized microbial surveillance in cystic fibrosis (CF), transforming pathogen identification from culture-dependent to total microbial community identification using molecular-based approaches. Techniques such as 16S rRNA gene sequencing have uncovered the complexity of the CF airway microbiome, while shotgun metagenomics, metatranscriptomics, and viromics now provide strain-level, functional, and viral insights beyond bacterial identification. Despite these advances, key technical and logistical challenges remain, including the processing of high-viscosity sputum samples, overwhelming host DNA contamination, managing large data sets, and the integration of complex bioinformatic outputs into clinical workflows. Emerging innovations such as host DNA depletion protocols, targeted enrichment panels, and adaptive sampling on Oxford Nanopore platforms are helping to overcome these barriers, improving microbial recovery and sequencing efficiency. As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies are changing the lives of people with cystic fibrosis (pwCF), sequencing offers an unprecedented opportunity to track potential microbial adaptation in response. This review investigates current advances, limitations, and translational opportunities in DNA sequencing for CF airway microbiome surveillance, highlighting how these technologies can help reshape research and clinical microbiology in the post-modulator era.
- 10 September 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 39 (3)
Open AccessDNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation
SUMMARY: DNA sequencing has revolutionized microbial surveillance in cystic fibrosis (CF), transforming pathogen identification from culture-dependent to total microbial community identification using molecular-based approaches. Techniques such as 16S rRNA gene sequencing have uncovered the complexity of the CF airway microbiome, while shotgun metagenomics, metatranscriptomics, and viromics now provide strain-level, functional, and viral insights beyond bacterial identification. Despite these advances, key technical and logistical challenges remain, including the processing of high-viscosity sputum samples, overwhelming host DNA contamination, managing large data sets, and the integration of complex bioinformatic outputs into clinical workflows. Emerging innovations such as host DNA depletion protocols, targeted enrichment panels, and adaptive sampling on Oxford Nanopore platforms are helping to overcome these barriers, improving microbial recovery and sequencing efficiency. As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies are changing the lives of people with cystic fibrosis (pwCF), sequencing offers an unprecedented opportunity to track potential microbial adaptation in response. This review investigates current advances, limitations, and translational opportunities in DNA sequencing for CF airway microbiome surveillance, highlighting how these technologies can help reshape research and clinical microbiology in the post-modulator era.
- Open Access
Microbial Ecological Signatures Predict Pathogen Emergence and Multidrug Resistance in Cystic Fibrosis Airways up to a Year in Advance
Chronic infections in cystic fibrosis (CF) emerge from gradual ecological transitions in the airway microbiome, yet early predictive markers remain poorly defined. We developed a new autoencoder-based framework that outperforms read-based or metagenome-assembled genome-based analyses at capturing the continuum from health-associated commensals to pathogen-dominated, antibiotic-tolerant communities. This improvement is achieved by integrating taxonomic and functional data from 127 sputum and bronchoalveolar lavage metagenomes from 64 people with CF into latent “Clusters of Phylogeny and Functions” (COPFs). Coupled with gradient-boosted random forests, COPFs predicted Pseudomonas aeruginosa colonisation, multidrug resistance, and impending infection up to a year before clinical detection. The multidrug-resistant P. aeruginosa signature showed the same resistance-mechanism evolution as found in laboratory experiments. The inclusion of eukaryotic markers revealed persistent Aspergillus fumigatus signatures even during culture-negative intervals. Applying our South Australian-trained model to over 1,000 global metagenomes from 22 independent CF datasets, we achieved 94% accuracy in predicting P. aeruginosa status across platforms and geographies, validating the model’s universal utility. Our results demonstrate that combining datasets with deep learning reveals conserved ecological and metabolic mechanisms in disease progression, transforming metagenomics into a predictive framework for managing chronic infections.
Open AccessMicrobial Ecological Signatures Predict Pathogen Emergence and Multidrug Resistance in Cystic Fibrosis Airways up to a Year in Advance
Chronic infections in cystic fibrosis (CF) emerge from gradual ecological transitions in the airway microbiome, yet early predictive markers remain poorly defined. We developed a new autoencoder-based framework that outperforms read-based or metagenome-assembled genome-based analyses at capturing the continuum from health-associated commensals to pathogen-dominated, antibiotic-tolerant communities. This improvement is achieved by integrating taxonomic and functional data from 127 sputum and bronchoalveolar lavage metagenomes from 64 people with CF into latent “Clusters of Phylogeny and Functions” (COPFs). Coupled with gradient-boosted random forests, COPFs predicted Pseudomonas aeruginosa colonisation, multidrug resistance, and impending infection up to a year before clinical detection. The multidrug-resistant P. aeruginosa signature showed the same resistance-mechanism evolution as found in laboratory experiments. The inclusion of eukaryotic markers revealed persistent Aspergillus fumigatus signatures even during culture-negative intervals. Applying our South Australian-trained model to over 1,000 global metagenomes from 22 independent CF datasets, we achieved 94% accuracy in predicting P. aeruginosa status across platforms and geographies, validating the model’s universal utility. Our results demonstrate that combining datasets with deep learning reveals conserved ecological and metabolic mechanisms in disease progression, transforming metagenomics into a predictive framework for managing chronic infections.
- Open Access
- 4 October 2022
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 45 (5) , 171-175
Drug treatment of cystic fibrosis
The life expectancy of patients with cystic fibrosis has improved so much, they are now experiencing chronic health conditions such as cardiovascular disease.
- 4 October 2022
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 45 (5) , 171-175
Open AccessDrug treatment of cystic fibrosis
The life expectancy of patients with cystic fibrosis has improved so much, they are now experiencing chronic health conditions such as cardiovascular disease.
- 16 October 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (1) , e28751
A randomized controlled trial of a structured exercise intervention after the completion of acute cancer treatment in adolescents and young adults
Background: Cancer treatments are frequently associated with impaired physical fitness, quality of life (QOL), and fatigue, often persisting into survivorship. Studies in older adults with cancer have demonstrated benefits from exercise; however, this has not been rigorously investigated in adolescents and young adults (AYA). The aim of this study was to determine whether a structured 10‐week exercise intervention was associated with improved cardiorespiratory fitness (VO2peak), fatigue, and QOL in AYA who have recently completed cancer treatment.Method: Forty‐three AYA (median age 21 ± 6 years) were randomly assigned to an exercise group (n = 22) or a control group (n = 21). The exercise group received a structured 10‐week exercise program comprising progressive aerobic and resistance exercise; the control arm received routine care. VO2peak was measured at baseline, 10 weeks, and six months. Fatigue and QOL were assessed by the FACIT fatigue scale and the PEDS QL, respectively.Results: Mean VO2peak at baseline was 26.5 ± 7.2 mL.kg−1.min−1, which is substantially lower than population norms. The exercise group demonstrated significant improvement in VO2peak at 10 weeks compared with controls (33.8 ± 8.1 vs 29.6 ± 7.6 mL.kg−1.min−1, P = 0.0002), but by six months, the difference was no longer significant (32.9 ± 7.0 vs 30.9 ± 11.0 mL.kg−1.min−1, P = 0.21). There were no significant differences in fatigue or total QOL scores between groups.Conclusion: Cancer treatment is associated with reduced VO2peak in AYA. Improvement in VO2peak was accelerated by a 10‐week exercise program; however, no significant benefit was observed in QOL or fatigue. The plateau in VO2peak at six months suggests that a maintenance exercise program may be beneficial.
- 16 October 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (1) , e28751
A randomized controlled trial of a structured exercise intervention after the completion of acute cancer treatment in adolescents and young adults
Background: Cancer treatments are frequently associated with impaired physical fitness, quality of life (QOL), and fatigue, often persisting into survivorship. Studies in older adults with cancer have demonstrated benefits from exercise; however, this has not been rigorously investigated in adolescents and young adults (AYA). The aim of this study was to determine whether a structured 10‐week exercise intervention was associated with improved cardiorespiratory fitness (VO2peak), fatigue, and QOL in AYA who have recently completed cancer treatment.Method: Forty‐three AYA (median age 21 ± 6 years) were randomly assigned to an exercise group (n = 22) or a control group (n = 21). The exercise group received a structured 10‐week exercise program comprising progressive aerobic and resistance exercise; the control arm received routine care. VO2peak was measured at baseline, 10 weeks, and six months. Fatigue and QOL were assessed by the FACIT fatigue scale and the PEDS QL, respectively.Results: Mean VO2peak at baseline was 26.5 ± 7.2 mL.kg−1.min−1, which is substantially lower than population norms. The exercise group demonstrated significant improvement in VO2peak at 10 weeks compared with controls (33.8 ± 8.1 vs 29.6 ± 7.6 mL.kg−1.min−1, P = 0.0002), but by six months, the difference was no longer significant (32.9 ± 7.0 vs 30.9 ± 11.0 mL.kg−1.min−1, P = 0.21). There were no significant differences in fatigue or total QOL scores between groups.Conclusion: Cancer treatment is associated with reduced VO2peak in AYA. Improvement in VO2peak was accelerated by a 10‐week exercise program; however, no significant benefit was observed in QOL or fatigue. The plateau in VO2peak at six months suggests that a maintenance exercise program may be beneficial.
- 6 January 2017
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Successful survival of an extreme premature infant with cystic fibrosis
Extreme premature infants with cystic fibrosis typically do not survive the neonatal phase. This case report describes the youngest survivor of a premature infant with cystic fibrosis and highlights the importance of advanced neonatal care with cystic fibrosis therapy.
- 6 January 2017
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Successful survival of an extreme premature infant with cystic fibrosis
Extreme premature infants with cystic fibrosis typically do not survive the neonatal phase. This case report describes the youngest survivor of a premature infant with cystic fibrosis and highlights the importance of advanced neonatal care with cystic fibrosis therapy.
- 1 September 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (9) , 2395-2398
Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples
Culture-based detection of nontuberculous Mycobacteria (NTM) in respiratory samples is time consuming and can be subject to overgrowth by nonmycobacterial bacteria. We describe a single-reaction TaqMan quantitative PCR assay for the direct detection of NTM species in clinical samples that is specific, sensitive, and robust.
- 1 September 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (9) , 2395-2398
Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples
Culture-based detection of nontuberculous Mycobacteria (NTM) in respiratory samples is time consuming and can be subject to overgrowth by nonmycobacterial bacteria. We describe a single-reaction TaqMan quantitative PCR assay for the direct detection of NTM species in clinical samples that is specific, sensitive, and robust.
- 1 March 2016
- Published by American Academy of Pediatrics (AAP) in NeoReviews
- Vol. 17 (3) , e166-e169
Case 2: A Late Preterm Newborn with Cyanosis
- 1 March 2016
- Published by American Academy of Pediatrics (AAP) in NeoReviews
- Vol. 17 (3) , e166-e169
Case 2: A Late Preterm Newborn with Cyanosis